Patent ID: 8293716
Filing Date: 2012-10-23
Classification: A61K,C07K

Abstract:
1. A method of decreasing vesicular shedding of complement from cancer cells and increasing complement-mediated cytolysis of cancer cells, thereby augmenting the cytolytic effect of antibodies that bind to cancer cells and recruit complement thereto, wherein the cancer cells are lymphoma/leukemia cells, colorectal cancer cells or bladder cancer cells, comprising: administering to the cancer cells antibodies that specifically bind the cancer cells and include a moiety capable of initiating complement-mediated cytotoxicity, and decreasing the level of a polypeptide of SEQ ID NO:1 (mortalin) in cancer cells by administering to the cancer cells a mortalin-specific siRNA molecule, which is capable of decreasing the level of expression of mortalin in the cancer cells, wherein the mortalin-specific siRNA molecule is administered in an amount effective to decrease the level of expression of said mortalin by an amount sufficient to decrease vesicular shedding of complement from cancer cells and increase complement-mediated cytolysis of cancer cells, thereby augmenting the cytolytic effect of said antibodies.